BYM338 (Bimagrumab)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Sporadic Inclusion Body Myositis (sIBM)

Drug Information

Target Indication

Sporadic Inclusion Body Myositis (sIBM)

Clinical Trial

Last updated: 4/3/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Related Pipeline

Neovascular Age-related Macular Degeneration

Renal Interstitial Fibrosis

Pathological Myopia

Non-Small Cell Lung Cancer

Prostatic Neoplasms